Treatment with a CXCR2 antagonist, antileukinate (Ac-RRWWCR-NH(2)), or anti-CXCL-1 neutralizing antibody reduces inflammatory responses and protects mice from acute pancreatitis-associated ALI or bleomycin-induced acute lung injury [66]. This evidence concerns the gene CXCL1 and acute respiratory distress syndrome.